

June 2009

**ACCRN07**

ACCL0431 Sodium Thiosulfate for prevention of Cisplatin-induced ototoxicity (must participate in ACCL05C1)  
ACCL05C1 Ototoxicity assessment in children receiving Cisplatin

**ACUTE LYMPHOBLASTIC LEUKEMIA**

- 1) AALL0331 Standard Risk B-Precursor ALL
  - 2) AALL0232 High Risk B-Precursor ALL: Dex/ MTX vs. Dex/HD MTX vs Pred/MTX vs Pred/HD MTX **<31 yrs**  
Classification of ALL **<31yrs**
  - 3) AALL03B1 Late Isolated extramedullary relapse of ALL **<30 yrs**
  - 4) AALL02P2 Intermediate-risk Relapse B-Precursor ALL: std vs intensive VCR **<29.99yrs**
  - 5) AALL0433 Newly Dx T-Cell ALL: MTX, Nelarabine, Augmented BFM **<31 yrs**  
**Suspended for pt.'s with Downs Syndrome**
  - 7) AALL05B1 Collection and Banking relapsed ALL specimens **<31 yrs**
  - 8) AALL03N1 Adherence in Ethnic Population with Childhood ALL (**Closed to Caucasians and Hispanics**)
- 9) Erwinase Master Protocol: substitution of Erwinia Asparaginase for PEG-Asparaginase due to an allergic rxn for pts not already on a COG study.

**ACUTE MYELOID LEUKEMIA**

- 1) AAML0431 Treatment of Down Syndrome Children with AML and Myelodysplastic Syndrome (MDS) **<4 yrs**
- 2) AAML0531 Newly Dx AML: Conventional Chemotherapy +/- Mylotarg **<30 yrs**

**BIOLOGY**

- 1) IPACTR International Pediatric Adrenocortical Carcinoma Tumor Registry
- 2) ABTRO1B1 Collecting and Banking Research Specimens Including Rare Tumors

**BRAIN TUMORS**

- 1) ACNS0331 Limited target volume boost irradiation and reduced cranial radiotherapy and chemotherapy for std. risk medulloblastoma **<22 yrs**
- 2) ACNS02B3 Collecting and Banking Pediatric Brain Tumor Specimens **<25yrs**
- 3) ACNS0332 Carboplatin concomitantly with RT & Isotretinoin in other than average risk medulloblastoma /PNET  $\geq 3yrs$  and  $\leq 22yrs$
- 4) ACNS0334 Phase III Randomized Trial for Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children  $<36$  Months Old with Intensive Induction Chemotherapy With or Without Methotrexate Followed by Consolidation with Stem Cell Rescue

**Hepatoblastoma**

- 1) POG 9346 Hepatoblastoma Biology Study and Tissue Bank
- 2) AEPI04C1 Low Birth Weight & Other Risk Factors for Hepatoblastoma

**HODGKIN DISEASE**

- 1) AHOD0031 A Phase III Study of Chemotherapy and Radiation Therapy for Children and Adolescents with Newly Diagnosed Intermediate Risk Hodgkin Disease – ABVE-PC (+DECA for slow responders) **<22 yrs**
- 2) AHOD03P1 Newly Dx Low Stage Lymphocyte Predominant HD – AV-PC **<22 yrs**
- 3) AHOD04B1 Hodgkin Disease Banking Study **<22 yrs** AHOD0521 refractory/recurrent Hodgkins: Bortezomib with Ifosfamide/Vinorelbine **<30yrs - temp closed 4/28/09**

**LYMPHOMA**

- 1) ANHL0131 A Phase III Study of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma with Standard APO vs. Consolidation with a Regimen Including Vinblastine **<21 yrs Temp Closed 12/11/08**
- 2) ANHL01P1 Addition of Rasburicase and Rituxan to Therapy for Advanced B-Cell Leukemia/Lymphoma **Only Treatment #4 is open to accrual. <30 yrs Temp Closed 02/23/09**

**NEUROBLASTOMA**

- 1) ANBL00B1 Neuroblastoma Biology Study **<31 yrs**
- 2) ANBL0032 High Risk Neuroblastoma s/p ASCT – Cis retinoic acid vs. cis retinoic acid + Ch14.18/GMCSF/IL-2 **<31 yrs**
- 3) ANBL0532 Phase III Randomized Trial of Single vs Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma **<30 yrs**
- 4) ANBL0531 Intermediate Risk Neuroblastoma  **$\leq 12$  yrs**

**SARCOMAS**

- 1) D9902 A COG Protocol for Collecting and Banking Soft Tissue Sarcoma Specimens **<50 yrs**
- 2) AEWS07B1 Collection & Banking Ewing Sarcoma
- 3) AEWS0331 Ewing's Sarcoma with Pulmonary Metastasis Only **<50 yrs**
- 4) AOST06B1 Collection & Banking Osteosarcoma Specimens
- 5) AOST0331 Resectable Osteosarcoma **<40 yrs**
- 6) ARET0332 Unilateral Retinoblastoma with & without histopathologic high-risk features and the role of adjuvant chemotherapy
- 7) ARST0331 VAC +/- Radiation for Low Risk Rhabdo **<50 yrs (subset 2 suspended)**
- 8) ARST0332 Risk-Based treatment for Non-Rhabdo soft tissue sarcoma (NRSTS)
- 9) ARST0531 VAC vs VAC alternating with VI Intermediate Risk Rhabdo **<50 yrs**

**SOLID TUMORS**

- 1) AGCT0132 Reduced Therapy for Low & Intermediate Risk Extracranial Germ Cell Tumors
- 2) AREN03B2 Renal Tumor Classification **<30 yrs**
- 3) AREN0321 High Risk Renal Tumors **\*\* Enrollment of patients with Stage III/IV Malignant Rhabdoid Tumors to the Irinotecan/Vincristine window (stratum 20) is suspended. Immediate suspension of accrual of patients to the Regimen UH-1 and Window Therapy arms. 10/31 <30 yrs**

**WILMS TUMOR**

- 1) 9442 (aka Protocol 4941L) National Wilms Tumor Late Effects Study
- 2) AREN0532 Treatment for very low, low and standard risk, fav. Histology, Wilms Tumor **<30 yrs**
- 3) AREN0533 Treatment for higher risk, favorable histology, Wilms Tumor **<30 yrs**

**LATE EFFECTS**

- 1) 9442 National Wilms Tumor Late Effects Study
- 2) ALTE05N1 Umbrella Long Term Follow-up